Poly Medicure Limited

BSE: 531768 NSE: POLYMED
Poly Medicure Limited - healthcare in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN L40300DL1995PLC066923 Incorporated 30 March 1995 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: POLYMED · BSE: 531768 Public Limited Company healthcare Nifty 500
Data last updated
Market Cap
₹14,686 Cr
POLYMED · NSE
Share Price
₹1,444.00
-0.34% today
Revenue
₹1,875 Cr
FY 2025-26 · +12.3% YoY
EBITDA
₹439 Cr
Margin 23.4%
Net Profit
₹265 Cr
FY 2025-26 · -6.6% YoY
P/E (TTM)
46.6x
P/B 4.8x
ROE
9.0%
ROCE 12.4%
Debt / Equity
0.09
Interest cover 6.6x

About Poly Medicure Limited

Data last updated:

Poly Medicure Limited is a public limited company based in New Delhi, Delhi, India. It operates in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 30 March 1995 and has been in existence for over 31 years.

Poly Medicure is part of the Nifty 500 and BSE 500 indices. Its director Jugal Kishore Baid and family are #416 among India's richest people (2026). Its director Vishal Gupta and family are #824 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L40300DL1995PLC066923. Its GSTIN is 07AAACP3891P1ZT (Delhi). The company holds 6 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 531768 and NSE: POLYMED.

The company has an authorised share capital of ₹60 Cr and a paid-up capital of ₹50.68 Cr. It is led by directors including Himanshu Baid (Managing Director) and Rishi Baid (Whole-Time Director).

Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Property No. – 232B Third Floor Okhla Industrial Estate Phase – III, New Delhi, Delhi, India – 110020.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,875.26 Cr, a growth of 12.3% compared to the previous year. For the same year it recorded a net profit of ₹264.92 Cr (net margin 14.1%) and EBITDA of ₹438.63 Cr (EBITDA margin 23.4%). The net worth stands at ₹3,106.17 Cr (up 12.3% YoY). Total assets are valued at ₹3,581.4 Cr (up 21% YoY).

The company has about 2,683 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Polymedicure. As per MCA filings, the company has open charges of ₹549.5 Cr and satisfied charges of ₹140.2 Cr on record. Court records list 150 cases involving the company, including 96 filed by the company and 54 filed against it; 21 cases are pending. The company has 23 deals on record (18 market trades, 2 secondary share transfers, 2 qips); the latest was in January 2026. The company has 4 MSME Form 1 returns on record between 2017 and 2021, listing 106 overdue payments to 17 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website polymedicure.com.

Company details

CIN L40300DL1995PLC066923
Registration Number 066923
Incorporation Date 30 March 1995
ROC Delhi
Listing Status Listed - Listed on NSE (POLYMED); Listed on BSE (531768)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Poly Medicure has one previous CIN (Corporate Identification Number): L74899DL1995PLC066923. The current CIN is L40300DL1995PLC066923, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L40300DL1995PLC066923Current
L74899DL1995PLC066923Previous
Key People
Himanshu Baid Managing Director Rishi Baid Whole-Time Director Pankaj Kumar Gupta Whole-Time Director

Recognitions & Rankings of Poly Medicure

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#205
Valuation
₹29,240 Cr
2023 #290 2022 #363 2021 #362
Stock market indices
Nifty 500 BSE 500

Contact details

Poly Medicure Limited's registered office is in New Delhi, Delhi. Its website is polymedicure.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    polymedicure.com
  • Social Media
  • Registered Address
    Property No. – 232B Third Floor Okhla Industrial Estate Phase – III, New Delhi, Delhi, India – 110020
  • Industry
    Healthcare, Medical & Laboratory Equipment

To see the full contact details of Poly Medicure Limited, buy the company report.

Comprehensive company report
Poly Medicure Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Poly Medicure operates one associated brand: Polymedicure. Each brand links to its own profile.

BrandDescriptionWebsite
Polymedicure
Medical devices for oncology, dialysis, and respiratory care are manufactured.polymedicure.com

Business activity

The main business activity of Poly Medicure is manufacturing. In detail, this covers plastic products, non-metallic mineral products, rubber products, fabricated metal products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC8Plastic products, non-metallic mineral products, rubber products, fabricated metal products

To see the full business activity and turnover split of Poly Medicure Limited, buy the company report.

Financials of Poly Medicure Limited

FY 2025-26 filings available

Poly Medicure Limited reported revenue of ₹1,875.26 Cr (up 12.3% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,875 Cr
+12.3% YoY
EBITDA
₹439 Cr
-3.8% YoY
Profit After Tax
₹265 Cr
-6.6% YoY
Net Worth
₹3,106 Cr
+12.3% YoY
Total Assets
₹3,581 Cr
+21.0% YoY
Total Debt
₹354 Cr
+96.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,8751,6701,3761,115923786687
Revenue growth+12.3%+21.4%+23.4%+20.8%+17.4%+14.4%-
EBITDA439456360267215216166
EBITDA margin+23.4%+27.3%+26.2%+24.0%+23.3%+27.5%+24.2%
Profit before tax427453344237195180126
Net profit26528425917214113595.77
Net profit margin+14.1%+17.0%+18.8%+15.4%+15.2%+17.2%+13.9%
EPS (₹)31.7833.4126.9118.6915.2814.1710.86
Balance sheet
Total assets3,5812,9591,6541,3991,2221,111648
Net worth3,1062,7661,4701,2421,087966435
Total debt354180174149127137207
Cash & bank87.8715114718315.4429.5625.36
Net working capital923676522525308260198
Cash flow
Cash from operations246233266191123119131
Cash from investing(224)(1,187)(241)(179)(85.33)(436)(109)
Cash from financing20.15951(20.15)(12.51)(35.34)317(20.51)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue525535494444403441424420
Revenue growth (YoY)+30.3%+21.3%+16.4%+5.7%+4.8%---
Other income34.9619.4727.9534.9143.4426.5823.5226.85
EBITDA125110104115106119115115
EBITDA margin+23.8%+20.7%+21.1%+25.8%+26.2%+27.1%+27.0%+27.4%
Depreciation36.2538.2328.7624.9323.2621.0321.5120.71
Interest6.506.415.962.972.952.173.333.34
Profit before tax11785.2397.61122123123113118
Tax32.0320.1826.8029.9029.8731.0228.0030.53
Net profit85.2865.0570.8191.7993.0791.8285.2287.46
EPS (₹)8.486.536.999.069.178.928.489.01
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,6621,6021,3071,068879747646
Revenue growth+3.8%+22.5%+22.4%+21.5%+17.7%+15.7%-
EBITDA441448351266214210162
EBITDA margin+26.6%+28.0%+26.9%+24.9%+24.3%+28.2%+25.1%
Profit before tax448443335237195173122
Net profit27927723617213312992.27
Net profit margin+16.8%+17.3%+18.1%+16.1%+15.1%+17.2%+14.3%
EPS (₹)33.1532.7026.2318.6615.2313.5110.47
Balance sheet
Total assets3,3212,9271,6311,3781,1941,087629
Net worth3,0532,7441,4581,2341,077954429
Total debt252172164137111126194
Cash & bank42.581431371718.3127.4022.39
Net working capital729640486486281241181
Cash flow
Cash from operations245230256197126116127
Cash from investing(268)(1,184)(237)(189)(88.71)(434)(106)
Cash from financing28.03953(17.32)(7.89)(39.71)319(22.25)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue431443419417384421411402
Revenue growth (YoY)+12.3%+5.2%+1.9%+3.5%+4.5%---
Other income28.6515.1229.5533.7241.5223.9521.7527.24
Total expenses310322313305283305295290
EBITDA121121105111101116115113
EBITDA margin+28.0%+27.3%+25.2%+26.7%+26.4%+27.6%+28.1%+28.0%
Depreciation26.4725.5125.0624.1522.8421.3320.6919.97
Interest4.383.893.942.782.812.173.133.13
Profit before tax119107106118117116113117
Tax30.5226.1827.6328.9629.1429.8428.2429.71

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue525535494444403441424420
Revenue growth (YoY)+30.3%+21.3%+16.4%+5.7%+4.8%---
Other income34.9619.4727.9534.9143.4426.5823.5226.85
EBITDA125110104115106119115115
EBITDA margin+23.8%+20.7%+21.1%+25.8%+26.2%+27.1%+27.0%+27.4%
Depreciation36.2538.2328.7624.9323.2621.0321.5120.71
Interest6.506.415.962.972.952.173.333.34
Profit before tax11785.2397.61122123123113118
Tax32.0320.1826.8029.9029.8731.0228.0030.53
Net profit85.2865.0570.8191.7993.0791.8285.2287.46
EPS (₹)8.486.536.999.069.178.928.489.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,8751,6701,3761,115923786687
Revenue growth+12.3%+21.4%+23.4%+20.8%+17.4%+14.4%-
Other income12694.3161.2738.1140.3521.7320.60
Total expenses1,4371,2141,016848708570521
Employee cost402302246203164142139
EBITDA439456360267215216166
EBITDA margin+23.4%+27.3%+26.2%+24.0%+23.3%+27.5%+24.2%
Depreciation11683.1863.4457.1753.9547.5240.53
Interest21.4214.3213.5610.866.1610.6420.48
Profit before tax427453344237195180126
Tax10711486.0158.2148.7444.1829.85
Net profit26528425917214113595.77
Net profit margin+14.1%+17.0%+18.8%+15.4%+15.2%+17.2%+13.9%
EPS (₹)31.7833.4126.9118.6915.2814.1710.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital50.6850.6647.9947.9747.9547.9444.12
Reserves & surplus3,0552,7151,4221,1941,040918391
Shareholders' funds (net worth)3,1062,7661,4701,2421,087966435
Minority interest43.070.000.000.000.000.000.00
Secured loans254175166140118129200
Unsecured loans99.815.557.758.539.008.066.97
Total debt354180174149127137207
Total liabilities3,5812,9591,6541,3991,2221,111648
Assets
Gross block2,4741,5961,3121,025822712605
Net block1,6941,084867635488426363
Capital work in progress98.7210175.7178.1643.4021.2124.71
Investments7551,07616712634635425.39
Inventories434286221209168126112
Sundry debtors531350270235207156127
Cash & bank balances87.8715114718315.4429.5625.36
Loans & advances15079.8064.2461.2756.4147.1837.30
Total current assets1,203866702688447359302
Total current liabilities27919118016313899.21104
Net working capital923676522525308260198
Total assets3,5812,9591,6541,3991,2221,111648
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash8.7012.057.067.764.954.864.32
Net cash from operating activities246233266191123119131
Net cash from investing activities(224)(1,187)(241)(179)(85.33)(436)(109)
Net cash from financing activities20.15951(20.15)(12.51)(35.34)317(20.51)
Net change in cash42.53(3.35)4.99(0.70)2.800.100.54
Closing cash87.8715114718315.4429.5625.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.3%+21.4%+23.4%+20.8%+17.4%+14.4%-
EBITDA growth-3.8%+26.6%+34.6%+24.4%-0.7%+30.3%-
PBT growth-5.5%+31.4%+45.0%+21.6%+8.4%+43.2%+25.6%
Net income growth-6.6%+9.7%+50.3%+22.3%+4.1%+41.1%-
Revenue CAGR (3Y)+18.9%+21.9%+20.5%+17.5%+14.8%+14.8%+14.7%
EBITDA CAGR (3Y)+17.9%+28.5%+18.5%+17.2%+17.9%+21.1%+21.1%
Profitability & leverage
Net income margin+17.1%+20.3%+18.8%+16.1%+15.9%+17.3%+14.0%
Return on capital employed+12.4%+20.2%+23.4%+19.0%+17.3%+21.7%+24.4%
Return on net worth+9.0%+16.0%+19.1%+15.4%+14.3%+19.4%+23.5%
Debt / equity0.090.080.120.120.130.250.45
Long-term debt / equity0.010.000.010.020.050.130.25
Interest cover6.633.844.575.173.826.3016.31
Efficiency & per share
Fixed asset turnover0.921.151.181.211.201.191.23
Inventory turnover5.216.596.405.926.266.597.02
Debtors turnover4.265.395.445.055.095.565.38
EPS (₹)31.7833.4126.9118.6915.2814.1710.86
Dividend per share (₹)3.503.503.003.002.502.502.00
Book value per share (₹)306.45272.95153.18129.41113.40100.7149.27
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue431443419417384421411402
Revenue growth (YoY)+12.3%+5.2%+1.9%+3.5%+4.5%---
Other income28.6515.1229.5533.7241.5223.9521.7527.24
Total expenses310322313305283305295290
EBITDA121121105111101116115113
EBITDA margin+28.0%+27.3%+25.2%+26.7%+26.4%+27.6%+28.1%+28.0%
Depreciation26.4725.5125.0624.1522.8421.3320.6919.97
Interest4.383.893.942.782.812.173.133.13
Profit before tax119107106118117116113117
Tax30.5226.1827.6328.9629.1429.8428.2429.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,6621,6021,3071,068879747646
Revenue growth+3.8%+22.5%+22.4%+21.5%+17.7%+15.7%-
Other income12089.7758.1836.2938.7319.2918.58
Total expenses1,2211,154956802665537484
Employee cost313280229188150131127
EBITDA441448351266214210162
EBITDA margin+26.6%+28.0%+26.9%+24.9%+24.3%+28.2%+25.1%
Depreciation97.9081.3961.5755.6452.5446.3139.28
Interest15.5213.5012.8510.195.369.9519.76
Profit before tax448443335237195173122
Tax11211283.1757.7848.7043.8729.40
Net profit27927723617213312992.27
Net profit margin+16.8%+17.3%+18.1%+16.1%+15.1%+17.2%+14.3%
EPS (₹)33.1532.7026.2318.6615.2313.5110.47
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital50.6850.6647.9947.9747.9547.9444.12
Reserves & surplus3,0022,6941,4101,1861,029906385
Shareholders' funds (net worth)3,0532,7441,4581,2341,077954429
Secured loans248170160135109123190
Unsecured loans3.192.603.942.581.433.294.32
Total debt252172164137111126194
Total liabilities3,3212,9271,6311,3781,1941,087629
Assets
Gross block1,7941,5361,255965768660555
Net block1,2171,047831598451390328
Capital work in progress95.8592.7970.7177.7442.9721.1824.58
Investments1,2431,12622118138438557.95
Inventories281250193183150109101
Sundry debtors442340259221191149120
Cash & bank balances42.581431371718.3127.4022.39
Loans & advances13476.6563.0056.4854.3942.9633.58
Total current assets900810652631404329277
Total current liabilities17117016614512387.7296.10
Net working capital729640486486281241181
Total assets3,3212,9271,6311,3781,1941,087629
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.552.140.380.632.791.892.91
Net cash from operating activities245230256197126116127
Net cash from investing activities(268)(1,184)(237)(189)(88.71)(434)(106)
Net cash from financing activities28.03953(17.32)(7.89)(39.71)319(22.25)
Net change in cash5.39(1.59)1.76(0.25)(2.16)0.90(1.02)
Closing cash42.581431371718.3127.4022.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.8%+22.5%+22.4%+21.5%+17.7%+15.7%-
EBITDA growth-1.5%+27.6%+31.8%+24.5%+1.7%+29.7%-
PBT growth+1.1%+32.2%+41.4%+21.6%+12.3%+42.4%+21.2%
Net income growth+0.9%+17.0%+37.5%+29.2%+3.3%+39.6%-
Revenue CAGR (3Y)+15.9%+22.1%+20.5%+18.2%+14.4%+13.7%+13.7%
EBITDA CAGR (3Y)+18.3%+28.0%+18.6%+18.0%+16.9%+20.1%+19.9%
Profitability & leverage
Net income margin+20.2%+20.7%+19.3%+16.8%+16.6%+17.3%+14.3%
Return on capital employed+13.4%+20.0%+23.1%+19.2%+17.5%+21.4%+24.2%
Return on net worth+9.6%+15.8%+18.7%+15.5%+14.4%+18.7%+22.8%
Debt / equity0.070.080.110.110.120.230.43
Long-term debt / equity0.000.000.010.020.050.130.25
Interest cover4.523.684.444.843.326.0716.07
Efficiency & per share
Fixed asset turnover1.001.151.181.231.231.231.27
Inventory turnover6.267.236.966.416.777.117.38
Debtors turnover4.255.345.445.185.175.555.28
EPS (₹)33.1532.7026.2318.6615.2313.5110.47
Dividend per share (₹)3.503.503.003.002.502.502.00
Book value per share (₹)301.18270.83151.95128.63112.3099.5048.65

To see the full year-wise statements and ratios of Poly Medicure Limited, buy the company report.

Board of directors and KMP of Poly Medicure Limited

Poly Medicure Limited currently reports 14 directors and 1 key managerial person. 10 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Vishal Gupta
Also directs: Woodstory LLP, Semac Construction Limited, Ashiana Housing Limited and 5 more
Director28 Oct 20241 Years 11 MonthsCurrent
Alessandro BalboniAdditional Director10 May 20188 Years 5 MonthsCurrent
Ambrish MithalDirector04 Aug 20224 Years 2 MonthsCurrent
Avinash ChandraCompany Secretary01 May 201511 Years 5 MonthsCurrent
Vimal Bhandari
Also directs: Kec International Limited, Escorts Kubota Limited, JK Lakshmi Cement Limited and 1 more
Director22 Jul 20242 Years 3 MonthsCurrent
Sonal Mattoo
Also directs: Syntegon Telstar India Private Limited, Pramerica Life Insurance Limited
Director29 Aug 20206 Years 1 MonthsCurrent
Showing 6 of 15 current directors and KMP. View all directors and KMP

Auditor

Poly Medicure Limited is audited by M C BHANDARI & CO. for the financial year 2023.

Auditor firmFinancial yearFirm registration number
M C BHANDARI & CO.FY 2023303002E

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 62.40%, foreign institutional investors hold 5.60%, domestic institutional investors hold 16.00% and retail and other public shareholders hold 16.00%.

Promoters: 62.40%DII (Domestic Institutional): 16.00%FII (Foreign Institutional): 5.60%Retail & Others: 16.00%
Sep 2026
QUARTER
62.40% Promoters
16.00% DII (Domestic Institutional)
5.60% FII (Foreign Institutional)
16.00% Retail & Others
Promoter holding - history
Now 62.40% · Sep 2026High 62.40% · Dec 2025Low 62.40% · Dec 2025
61%61.8%62.5%63.3%64%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 62.40%Mar 2026: 62.40%Jun 2026: 62.40%Sep 2026: 62.40%62.40%62.40%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters62.40%62.40%62.40%62.40%
Public37.60%37.60%37.60%37.60%

Charges & borrowings

Open charges
₹549.5 Cr
Satisfied charges
₹140.2 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹402.00 Cr
Hdfc Bank Limited₹112.50 Cr
Citi Bank N.A.₹25.00 Cr
The Hongkong and Shanghai Banking Corporation Limited₹10.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
27 Apr 2026101294435Hdfc Bank Limited₹70 CrOpen
18 Apr 2025101121003Hdfc Bank Limited₹30 CrOpen
07 Nov 2017100141255Hdfc Bank Limited₹12.5 CrOpen
14 Feb 2017100079259The Hongkong and Shanghai Banking Corporation Limited₹10 CrOpen
15 Jun 201110292924Citi Bank N.A.₹25 CrOpen

To see the full charge records of Poly Medicure Limited, buy the company report.

Total charge records: 11 View all charges

Deals & funding

Poly Medicure Limited has 23 deals on record (18 market trades, 2 secondary share transfers, 2 qips); the latest was in January 2026.

Total deals
23
Market trades
18
Secondary share transfers
2
QIPs
2
Rights issue
1

Deals on record (5 of 23)

WhenDealAmountParties
Aug 2024QIP₹1,000 CrInvestors: Others Poly Medicure Limited, Lighthouse Fund, SBI Healthcare Opportunities Fund
Oct 2012Market trade₹1.98 CrSeller: Aventis Biofeeds Private Limited
Dec 2011Market trade₹5.58 CrBuyer: Pentagon Builders Pvt Ltd
Seller: an individual
Sep 2011Market trade₹4.16 CrBuyer: KJMC Financial Services Limited
Seller: an individual
Sep 2011Market trade₹3.89 CrBuyer: KJMC Financial Services Limited
Seller: an individual

To see the full deal history of Poly Medicure Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Poly Medicure Limited was last rated by Crisil on 13 Jul 2020.

Rating agencyRated onRating
Crisil13 Jul 2020

To see the full credit ratings and regulatory alerts of Poly Medicure Limited, buy the company report.

MSME payment delays

Poly Medicure Limited has 4 MSME Form 1 returns on record between 2017 and 2021, listing 106 overdue payments to 17 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 17)

SupplierAmount dueDue sinceReported on
Rainbow Industries (India)
Madhyanchal Rubbers Private Limited
Mechmaark Filtech India Private Limited
Suparshva Swabs (I)
an individual supplier

To see the full MSME payment records of Poly Medicure Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Poly Medicure Limited has a workforce of 2,683 employees on its EPFO records as of Apr 05, 2024, across 9 active EPFO establishments.

Employee count
2,683
Active EPFO establishments
9
Employee growth
15.95%

GST

Poly Medicure has 6 GST registrations: 6 active. The first 4 active GSTINs are listed below.

Total GSTINs
6
Active
6
GSTINStateStatusRegistered on
07AAACP3891P1ZTDelhiActive01 Jul 2017
07AAACP3891P2ZSDelhiActive18 Aug 2017
05AAACP3891P1ZXUttarakhandActive01 Jul 2017
06AAACP3891P1ZVHaryanaActive01 Jul 2017

To see the full GST registrations and return filing status of Poly Medicure Limited, buy the company report.

Recent activity

Poly Medicure Limited has 20 board changes on record since 1995: 15 appointments and 5 cessations. The latest: Pankaj Kumar Gupta was appointed as Whole-Time Director on 08 Aug 2025.

Charges
A charge with Hdfc Bank Limited amounted to Rs. 70.00 Cr with Charge ID 101294435 was registered on 27 Apr 2026.
Filing
Poly Medicure Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi I.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 402.00 Cr registered on 08 Aug 2002 with Charge ID 90062621 was modified on 12 Feb 2026.
AGM
Poly Medicure Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Appointed
Pankaj Kumar Gupta was appointed as Whole-Time Director.
Appointed
Vishal Baid was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 30.00 Cr with Charge ID 101121003 was registered on 18 Apr 2025.
Appointed
Vishal Gupta was appointed as Director.
Charges
A charge registered on 09 Sep 2019 via Charge ID 100286988 with Others was fully satisfied on 18 Oct 2024.
Appointed
Vimal Bhandari was appointed as Director.
Ceased
Prakash Chand Surana ceased to be Director.
Charges
A charge registered on 30 Jul 2018 via Charge ID 100201954 with Others was fully satisfied on 16 May 2024.

34 earlier events are in the company report.

News

Govt May Tighten Medical-device Rules, Giving Licensing Authorities Power To Halt Manufacture And Sale Of Unsafe Products - Newspaper ( Poly Medicure )
22 Sep 2026 · Exchange Update

Frequently asked questions

Poly Medicure is an active public limited company based in New Delhi, Delhi, India. The company works in medical and laboratory equipment, within the healthcare industry. It was incorporated on 30 March 1995 (31+ years old) and is registered under CIN L40300DL1995PLC066923. Listed on BSE: 531768 and NSE: POLYMED.

Poly Medicure reported revenue of ₹1,875.26 Cr for FY 2025-26 (up 12.3% YoY) based on consolidated financials.

Poly Medicure has 15 current directors and KMP:

The latest financial statements of Poly Medicure on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Poly Medicure is 07AAACP3891P1ZT, registered in Delhi. The company has 6 GST registrations in all, of which 6 are active. Other active GSTINs include 07AAACP3891P2ZS (Delhi), 05AAACP3891P1ZX (Uttarakhand), 06AAACP3891P1ZV (Haryana).

The CIN (Corporate Identification Number) of Poly Medicure is L40300DL1995PLC066923. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Poly Medicure is a listed company as per MCA records. Its shares are listed on both BSE (code: 531768) and NSE (symbol: POLYMED).

Poly Medicure has 150 court cases on record: 96 filed by the company and 54 filed against it. 21 are pending. Most are in the district courts.

Poly Medicure was incorporated on 30 March 1995, making it 31+ years old. It is registered with the Registrar of Companies, Delhi.

Poly Medicure has 23 deals on record (18 market trades, 2 secondary share transfers, 2 qips); the latest was in January 2026.

Pankaj Kumar Gupta was appointed as Whole-Time Director on 08 Aug 2025. Vishal Baid was appointed as Director on 06 May 2025. Vishal Gupta was appointed as Director on 28 Oct 2024. Poly Medicure has 20 board changes on record in total.